Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5031989 | 0.74 | CCR2 (0.34) | LMNAMEN1KMT2A | |
| SCHEMBL1973469 | 0.72 | MEN1 (0.38) | LMNAMEN1KMT2AHSD11B1L3MBTL1 | |
| SCHEMBL1973468 | 0.72 | MEN1 (0.38) | LMNAMEN1KMT2AHSD11B1L3MBTL1 | |
| SCHEMBL5029421 | 0.72 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL12513277 | 0.71 | MEN1 (0.37) | LMNAMEN1KMT2AHSD11B1L3MBTL1 | |
| SCHEMBL22721991 | 0.71 | MEN1 (0.37) | LMNAMEN1KMT2AHSD11B1L3MBTL1 | |
| SCHEMBL22722020 | 0.71 | MEN1 (0.37) | LMNAMEN1KMT2AHSD11B1L3MBTL1 | |
| SCHEMBL5033604 | 0.69 | — | — | |
| SCHEMBL22722036 | 0.68 | MEN1 (0.41) | MEN1KMT2AALDH1A1 | |
| SCHEMBL5029177 | 0.68 | SMYD3 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | LMNA 4639/4885MEN1 3483/4885KMT2A 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.